Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans.

ABSTRACT: TLR8 agonists have the potential for use as immunomodulatory components in therapeutic modalities for viral infections such as chronic HBV (CHB) and HIV. In this study, using peripheral blood samples from a phase 1a clinical trial, we examined the acute effects of a single oral administration of a selective TLR8 agonist on immune cell phenotypes. Administration of the TLR8 agonist selgantolimod (SLGN) in healthy individuals resulted in alteration in frequencies of peripheral blood monocytes, pDCs, mDCs and MAIT cells. Frequencies of mDCs and lymphoid cells significantly reduced after 8 h of SLGN administration, whereas pDC frequencies significantly increased, with changes possibly reflecting migration of different cell types between peripheral and tissue compartments in response to the ago

SUBMITTER: Ayithan N 

PROVIDER: S-EPMC8706304 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature